Information Provided By: 
Fly News Breaks for October 25, 2019
ATRA
Oct 25, 2019 | 15:06 EDT
Mizuho analyst Salim Syed kept a Buy rating on Atara Biotherapeutics after following up with the company regarding the reported departure of Chief Scientific Officer Chris Haqq. The company confirmed to Syed that Haqq left his CSO position for family reasons, and accepted the role at Elicio, a smaller, private company, that is more suited to his family needs. The company added that Haqq would remain an advisor for Atara for at least six months, potentially for longer.
News For ATRA From the Last 2 Days
There are no results for your query ATRA
